Regeneron Pharmaceuticals has secured FDA accelerated approval for Linvoseltamab (Lynozyfic), a bispecific antibody targeting BCMA and CD3, for adult patients with relapsed or refractory multiple myeloma. This approval offers a dosing flexibility advantage over existing bispecific therapies from Johnson & Johnson and Pfizer. Continued approval depends on confirmatory trials. This expands therapeutic options in a challenging hematologic malignancy.